Skip to Content

Chimeric Therapeutics Ltd Ordinary Shares CHM

Rating as of

Morningstar’s Analysis

Valuation
Currency in AUD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells.

Contact
62 Lygon Street, Level 3, Carlton South
Melbourne, VIC, 3053, Australia
T +61 398245254
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Jun 30, 2021
Stock Type
Employees